{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:37:21Z","timestamp":1794886641704,"version":"4.9.1"},"reference-count":165,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment. Since 1989, 18 new AEDs have been licensed for clinical use and there are now 27 licensed AEDs in total for the treatment of patients with epilepsy. Furthermore, several AEDs are also used for the management of other medical conditions, for example, pain and bipolar disorder. This has led to an increasingly widespread application of therapeutic drug monitoring (TDM) of AEDs, making AEDs among the most common medications for which TDM is performed. The aim of this review is to provide an overview of the indications for AED TDM, to provide key information for each individual AED in terms of the drug's prescribing indications, key pharmacokinetic characteristics, associated drug\u2013drug pharmacokinetic interactions, and the value and the intricacies of TDM for each AED. The concept of the reference range is discussed as well as practical issues such as choice of sample types (total versus free concentrations in blood versus saliva) and sample collection and processing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The present review is based on published articles and searches in PubMed and Google Scholar, last searched in March 2018, in addition to references from relevant articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 171 relevant references were identified and used to prepare this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TDM provides a pragmatic approach to epilepsy care, in that bespoke dose adjustments are undertaken based on drug concentrations so as to optimize clinical outcome. For the older first-generation AEDs (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone, and valproic acid), much data have accumulated in this regard. However, this is occurring increasingly for the new AEDs (brivaracetam, eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, piracetam, pregabalin, rufinamide, stiripentol, sulthiame, tiagabine, topiramate, vigabatrin, and zonisamide).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000546","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T17:20:57Z","timestamp":1530206457000},"page":"526-548","source":"Crossref","is-referenced-by-count":467,"title":["Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update"],"prefix":"10.1097","volume":"40","author":[{"given":"Philip N.","family":"Patsalos","sequence":"first","affiliation":[{"name":"Epilepsy Society, Therapeutic Drug Monitoring Unit, Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire; and"},{"name":"Department of Clinical and Experimental Epilepsy, UCL-Institute of Neurology, Queen Square, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar P.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Epilepsy Society, Therapeutic Drug Monitoring Unit, Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave J.","family":"Berry","sequence":"additional","affiliation":[{"name":"Epilepsy Society, Therapeutic Drug Monitoring Unit, Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","article-title":"Therapeutic drug monitoring of antiepileptic drugs by use of saliva","volume":"35","author":"Patsalos","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1528-1157.1988.tb04408.x","article-title":"If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study","volume":"29","author":"Woo","year":"1988","journal-title":"Epilepsia."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies of antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Landmark","year":"2016","journal-title":"Epileptic Disord."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1111\/epi.12801","article-title":"Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study","volume":"55","author":"Samsonsen","year":"2014","journal-title":"Epilepsia."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1525-5050(03)00151-3","article-title":"Postictal serum levels of antiepileptic drugs for detection of noncompliance","volume":"4","author":"Specht","year":"2003","journal-title":"Epilepsy Behav."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1978.tb01685.x","article-title":"Compliance with anticonvulsant therapy in a hospital clinic and community","volume":"6","author":"Mucklow","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00019053-199711040-00005","article-title":"Indications for plasma drug monitoring in patients with epilepsy. Implications for reducing costs","volume":"11","author":"Eadie","year":"1997","journal-title":"Pharmacoeconomics."},{"key":"R11-20230814","first-page":"643","article-title":"Prevalence of toxic anticonvulsant drug concentrations in mentally retarded persons with epilepsy","volume":"90","author":"Aman","year":"1986","journal-title":"Am J Ment Defic."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2298\/VSP1205389D","article-title":"Toxicokinetics and correlation of carbamazepine salivary and serum concentrations in acute poisoning","volume":"69","author":"Djordjevic","year":"2012","journal-title":"Vosjnosanit Pregl."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1586\/14737175.7.2.179","article-title":"Antiepileptic drug treatment in children","volume":"7","author":"Hadjiloizou","year":"2007","journal-title":"Expert Rev Neurother."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update","volume":"52","author":"Italiano","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0387-7604(94)90108-2","article-title":"Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing","volume":"16","author":"Walson","year":"1994","journal-title":"Brain Dev"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00007691-199007000-00006","article-title":"Monitoring phenytoin therapy using citric acid-stimulated saliva in infants and children","volume":"12","author":"Lifshitz","year":"1990","journal-title":"Ther Drug Monit."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00007691-198103000-00008","article-title":"Monitoring of phenobarbitone and phenytoin therapy in small children by salivary samples","volume":"3","author":"Mucklow","year":"1981","journal-title":"Ther Drug Monit."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007691-199302000-00005","article-title":"Free phenytoin monitoring in serum and saliva of patients in China","volume":"15","author":"Cai","year":"1993","journal-title":"Ther Drug Monit."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00007691-200106000-00011","article-title":"Use of saliva in therapeutic drug monitoring of caffeine in preterm infants","volume":"23","author":"de Wildt","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0163-7258(87)90096-9","article-title":"Drug metabolism in pregnancy, infancy and childhood","volume":"34","author":"Perucca","year":"1987","journal-title":"Pharmacol Ther."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00003088-200746030-00002","article-title":"Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and puerperium","volume":"46","author":"Tomson","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1528-1167.2007.01032.x","article-title":"Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period and lactation","volume":"48","author":"Tomson","year":"2007","journal-title":"Epilepsia."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1528-1167.2006.00459.x","article-title":"Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium","volume":"47","author":"Mazzucchelli","year":"2006","journal-title":"Epilepsia."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eplepsyres.2009.08.004","article-title":"Pharmacokinetics of topiramate during pregnancy","volume":"87","author":"Ohman","year":"2009","journal-title":"Epilepsy Res."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1345\/aph.1L052","article-title":"Zonisamide concentrations during pregnancy","volume":"42","author":"Oles","year":"2008","journal-title":"Ann Pharmacother."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"19","DOI":"10.9758\/cpn.2017.15.1.19","article-title":"Teratogenicity of antiepileptic drugs","volume":"15","author":"G\u00fcveli","year":"2017","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/epi.13415","article-title":"Antiepileptic drug combinations not involving valproate and the risk of fetal malformations","volume":"57","author":"Vajda","year":"2016","journal-title":"Epilepsia."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/s-0035-1556741","article-title":"An update on maternal use of antiepileptic medications in pregnancy and neurodevelopment outcomes","volume":"4","author":"Gerard","year":"2015","journal-title":"J Pediatr Genet."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-related changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1528-1167.2005.00251.x","article-title":"Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?","volume":"46","author":"Ohman","year":"2005","journal-title":"Epilepsia."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1212\/WNL.61.6_suppl_2.S35","article-title":"Antiepileptic drug pharmacokinetics during pregnancy and lactation","volume":"61","author":"Pennell","year":"2003","journal-title":"Neurology."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2018.02.004","article-title":"Pharmacokinetic variability of valproate during pregnancy\u2014implications for the use of therapeutic drug monitoring","volume":"141","author":"Landmark","year":"2018","journal-title":"Epilepsy Res."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archfami.3.7.589","article-title":"Antiepileptic drugs in the elderly. Pharmacoepidemiology and pharmacokinetics","volume":"3","author":"Cloyd","year":"1994","journal-title":"Arch Fam Med."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ageing\/10.2.73","article-title":"Drug response in the elderly: sensitivity and pharmacokinetic considerations","volume":"10","author":"Crooks","year":"1981","journal-title":"Age Ageing."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2017.11.001","article-title":"Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: a pharmacoepidemiological study of CNS-active drugs in Norway, 2004\u20132015","volume":"139","author":"Baftiu","year":"2017","journal-title":"Epilepsy Res."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-198712010-00004","article-title":"Plasma protein binding of drugs in the elderly","volume":"12","author":"Wallace","year":"1987","journal-title":"Clin Pharmacokinet."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/00365517209102760","article-title":"Sequential changes of plasma proteins after surgical trauma","volume":"124","author":"Aronsen","year":"1972","journal-title":"Scand J Lab Invest Suppl."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-3565(25)32025-2","article-title":"Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients","volume":"213","author":"Bowdle","year":"1980","journal-title":"J Pharmacol Exp Ther."},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1984.73","article-title":"Plasma protein binding of drugs after severe burn injury","volume":"35","author":"Martyn","year":"1984","journal-title":"Clin Pharmacol Ther."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007691-199412000-00015","article-title":"Therapeutic drug monitoring of phenytoin in patients with acquired immunodeficiency syndrome","volume":"16","author":"Burger","year":"1994","journal-title":"Ther Drug Monit."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1528-1157.2001.08007.x","article-title":"Elderly patients with systemic disease","volume":"42","author":"Boggs","year":"2001","journal-title":"Epilepsia."},{"issue":"suppl 1","key":"R44-20230814","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-198400091-00009","article-title":"Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies","volume":"9","author":"Perucca","year":"1984","journal-title":"Clin Pharmacokinet."},{"issue":"suppl 1","key":"R45-20230814","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/j.1528-1157.1982.tb06092.x","article-title":"Use of antiepileptic drugs in the presence of liver and kidney disease: a review","volume":"23","author":"Asconape","year":"1982","journal-title":"Epilepsia."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug Interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokin."},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin Pharmacokin."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"issue":"suppl 5","key":"R51-20230814","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","article-title":"Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs","volume":"47","author":"Perucca","year":"2006","journal-title":"Epilepsia."},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology."},{"key":"R53-20230814","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1345\/aph.1P765","article-title":"Generic substitution of levetiracetam resulting in increased breakthrough seizures","volume":"45","author":"Fitzgerald","year":"2011","journal-title":"Ann Pharmacother."},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","article-title":"Compulsory generic substitution and antiepileptic drugs: high switchback rates to branded compounds compared to other drug classes","volume":"48","author":"Andermann","year":"2007","journal-title":"Epilepsia."},{"key":"R55-20230814","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical consequences of genetic substitution of lamotrigine for patients with epilepsy","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology."},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1528-1167.2008.01703.x","article-title":"Case-controlled analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes","volume":"50","author":"Zachry","year":"2009","journal-title":"Epilepsia."},{"key":"R57-20230814","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1212\/WNL.0b013e3181aa5300","article-title":"The risks and costs of multiple-generic substitution of topiramate","volume":"72","author":"Duh","year":"2009","journal-title":"Neurology."},{"key":"R58-20230814","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia."},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol."},{"key":"R60-20230814","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol."},{"key":"R61-20230814","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/epi.13802","article-title":"Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations","volume":"58","author":"Patsalos","year":"2017","journal-title":"Epilepsia."},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males","volume":"63","author":"Sargentini-Maier","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"R63-20230814","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","article-title":"Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects","volume":"36","author":"Sargentini-Maier","year":"2008","journal-title":"Drug Metab Dispo."},{"issue":"suppl 6","key":"R64-20230814","first-page":"333","article-title":"Population pharmacokinetics of brivaracetam in patients with partial epilepsy","volume":"48","author":"Lacroix","year":"2007","journal-title":"Epilepsia."},{"key":"R65-20230814","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Drug Des Develop Ther."},{"key":"R66-20230814","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men","volume":"66","author":"Rolan","year":"2008","journal-title":"Br J Clin Pharmacol."},{"key":"R67-20230814","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/clpt.1980.13","article-title":"Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique","volume":"127","author":"Bertilsson","year":"1980","journal-title":"Clin Pharmacol Ther."},{"key":"R68-20230814","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":"Autoinduction and steady-state pharmacokinetics of carbamazepine and its metabolites","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br J Clin Pharmacol."},{"key":"R69-20230814","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2125.1990.tb03682.x","article-title":"A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients","volume":"29","author":"Patsalos","year":"1990","journal-title":"Br J Clin Pharmacol."},{"key":"R71-20230814","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","article-title":"Brivaracetam and carbamazepine interaction in healthy subjects and in vitro","volume":"113","author":"Stockis","year":"2015","journal-title":"Epilepsy Res."},{"issue":"suppl 1","key":"R72-20230814","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ddr.430010716","article-title":"Aspects of pharmacokinetics and pharmacodynamics of benzodiazepines with particular reference to clobazam","author":"Aucamp","year":"1982","journal-title":"Drug Dev Res."},{"key":"R73-20230814","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1469-8749.2006.tb01325.x","article-title":"Clobazam toxicity in a child with epilepsy related to idiosyncratic metabolism","volume":"48","author":"Aylett","year":"2005","journal-title":"Dev Med Child Neurol."},{"key":"R74-20230814","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1212\/WNL.25.3.255","article-title":"Serum clonazepam concentrations in children with absence seizures","volume":"25","author":"Dreifuss","year":"1975","journal-title":"Neurology."},{"key":"R75-20230814","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/BF00542419","article-title":"Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures","volume":"30","author":"Andre","year":"1986","journal-title":"Eur J Clin Pharmacol."},{"key":"R76-20230814","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1528-1157.1975.tb06058.x","article-title":"Plasma levels of diazepam after parenteral and rectal administration","volume":"16","author":"Agurell","year":"1975","journal-title":"Epilepsia."},{"key":"R77-20230814","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00560461","article-title":"Plasma concentration of diazepam and N-desmethyldiazepam in children after a single rectal or intramuscular dose","volume":"12","author":"Meberg","year":"1978","journal-title":"Eur J Clin Pharmacol."},{"key":"R78-20230814","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1528-1157.1998.tb01415.x","article-title":"A single blind crossover comparison of the pharmacokinetic and cognitive effects of a new diazepam rectal gel with intravenous diazepam","volume":"39","author":"Cloyd","year":"1998","journal-title":"Epilepsia."},{"key":"R80-20230814","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.1982.tb01421.x","article-title":"Valproic acid and diazepam interaction in vivo","volume":"13","author":"Dhillon","year":"1982","journal-title":"Br J Clin Pharmacol."},{"key":"R82-20230814","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2125.1980.tb01059.x","article-title":"Diazepam and N-desmethyldiazepam concentrations in saliva, plasma and CSF","volume":"9","author":"Hallstrom","year":"1980","journal-title":"Br J Clin Pharmacol."},{"key":"R83-20230814","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","article-title":"Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans","volume":"44","author":"Almeida","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"R84-20230814","first-page":"213","article-title":"The absorption and excretion of ethosuximide","volume":"7","author":"Buchanan","year":"1973","journal-title":"Int J Clin Pharmacol."},{"key":"R85-20230814","first-page":"172","article-title":"Pharmacokinetics of drugs used for petit mal \u201cabsence\u201d epilepsy","volume":"14","author":"Eadie","year":"1977","journal-title":"Clin Exp Neurol."},{"key":"R86-20230814","first-page":"642","article-title":"Evaluation of the elimination of (14C) felbamate in healthy men","volume":"31","author":"Shumaker","year":"1990","journal-title":"Epilepsia."},{"key":"R87-20230814","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410320313","article-title":"Felbamate monotherapy: controlled trial in patients with partial onset seizures","volume":"32","author":"Sachdeo","year":"1992","journal-title":"Ann Neurol."},{"key":"R88-20230814","first-page":"830","article-title":"Pharmacokinetics and metabolism of gabapentin in rat, dog and man","volume":"36","author":"Vollmer","year":"1986","journal-title":"Azneimittelforschung."},{"key":"R89-20230814","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs","volume":"10","author":"Landmark","year":"2010","journal-title":"Expert Rev Neurother."},{"key":"R90-20230814","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":"Lacosamide","volume":"4","author":"Doty","year":"2007","journal-title":"Neurotherapeutics."},{"key":"R91-20230814","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2012.667803","article-title":"Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate","volume":"13","author":"Patsalos","year":"2012","journal-title":"Exp Opin Pharmacother."},{"key":"R92-20230814","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.12513","article-title":"Advances in epilepsy treatment: lacosamide pharmacokinetic profile","volume":"1329","author":"Cawello","year":"2014","journal-title":"Ann N Y Acad Sci."},{"key":"R93-20230814","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":"Lacosamide therapeutic monitoring in patients with epilepsy: effects of concomitant antiepileptic drugs","volume":"35","author":"Contin","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R94-20230814","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","article-title":"Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose and concomitant antiepileptic drugs","volume":"36","author":"Markoula","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R95-20230814","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem Res."},{"key":"R96-20230814","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1111\/epi.14023","article-title":"Assessment of correlations of lacosamide concentrations in saliva and serum in patients with epilepsy","volume":"59","author":"Brandt","year":"2018","journal-title":"Epilepsia."},{"key":"R97-20230814","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"5","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet."},{"key":"R98-20230814","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","article-title":"Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication","volume":"18","author":"May","year":"1996","journal-title":"Ther Drug Monit."},{"key":"R99-20230814","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther."},{"key":"R100-20230814","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/j.1528-1167.2006.00819.x","article-title":"In situ metabolism of levetiracetam in blood of patients with epilepsy","volume":"47","author":"Patsalos","year":"2006","journal-title":"Epilepsia."},{"key":"R101-20230814","first-page":"240","article-title":"Effective levetiracetam doses and serum concentrations: age effects","volume":"43","author":"Leppik","year":"2002","journal-title":"Epilepsia."},{"key":"R102-20230814","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00315422","article-title":"Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia","volume":"39","author":"Patsalos","year":"1990","journal-title":"Eur J Clin Pharmacol."},{"key":"R103-20230814","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin Pharmacol Ther."},{"key":"R104-20230814","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00023210-200115020-00005","article-title":"Oxcarbazepine-an update of its efficacy in the management of epilepsy","volume":"15","author":"Wellington","year":"2001","journal-title":"CNS Drugs."},{"key":"R105-20230814","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia."},{"key":"R106-20230814","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","article-title":"Phenobarbital pharmacokinetics and bioavailability in adults","volume":"22","author":"Nelson","year":"1982","journal-title":"J Clin Pharmacol."},{"key":"R107-20230814","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01061382","article-title":"Kinetics of phenobarbital in normal subjects and epileptic patients","volume":"23","author":"Wilensky","year":"1982","journal-title":"Eur J Clin Pharmacol."},{"key":"R108-20230814","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-197904030-00001","article-title":"Clinical pharmacokinetics of phenytoin","volume":"4","author":"Richens","year":"1979","journal-title":"Clin Pharmacokinet."},{"key":"R109-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-197904020-00002","article-title":"Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications","volume":"4","author":"Neurvonen","year":"1979","journal-title":"Clin Pharmacokinet."},{"key":"R110-20230814","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(01)06890-8","article-title":"Pyrrolidine derivatives","volume":"358","author":"Shorvon","year":"2001","journal-title":"Lancet."},{"key":"R111-20230814","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia."},{"key":"R112-20230814","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.22.11.1186","article-title":"Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration","volume":"22","author":"Gallagher","year":"1972","journal-title":"Neurology."},{"key":"R113-20230814","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<259::AID-BDD98>3.0.CO;2-V","article-title":"The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers","volume":"19","author":"Cardot","year":"1998","journal-title":"Biopharm Drug Dispos."},{"key":"R114-20230814","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia."},{"key":"R115-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","article-title":"Rufinamide: a novel broad-spectrum antiepileptic drug","volume":"10","author":"Wheless","year":"2010","journal-title":"Epilepsy Curr."},{"key":"R116-20230814","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1984.237","article-title":"Stiripentol kinetics in epilepsy: nonlinearity and interactions","volume":"36","author":"Levy","year":"1984","journal-title":"Clin Pharmacol Ther."},{"key":"R117-20230814","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","article-title":"Stiripentol","volume":"4","author":"Chiron","year":"2007","journal-title":"Neurotherapeutics."},{"key":"R118-20230814","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","article-title":"Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity","volume":"23","author":"Levy","year":"1983","journal-title":"J Clin Pharmacol."},{"key":"R119-20230814","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0090-9556(25)08990-1","article-title":"The metabolic fate of stiripentol in man","volume":"14","author":"Moreland","year":"1986","journal-title":"Drug Metab Dispos."},{"key":"R120-20230814","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet."},{"key":"R121-20230814","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1528-1157.1993.tb02416.x","article-title":"Stiripentol in atypical absence seizures in children: an open trial","volume":"34","author":"Farwell","year":"1993","journal-title":"Epilepsia."},{"key":"R122-20230814","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-199406000-00005","article-title":"Pharmacokinetics of sulthiame in epileptic patients","volume":"16","author":"May","year":"1994","journal-title":"Ther Drug Monit."},{"key":"R123-20230814","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1528-1157.1995.tb02575.x","article-title":"Pharmacokinetics of tiagabine, a \u03b3-aminobutyric acid-uptake inhibitor in healthy subjects after single and multiple doses","volume":"36","author":"Gustavson","year":"1995","journal-title":"Epilepsia."},{"key":"R124-20230814","first-page":"143","article-title":"Concentration-dependent displacement of tiagabine by valproic acid","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia."},{"key":"R125-20230814","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures. A randomized, add-on, dose-response trial","volume":"55","author":"Ulthman","year":"1998","journal-title":"Arch Neurol."},{"key":"R126-20230814","first-page":"155","article-title":"The pharmacokinetic profile of topiramate","volume":"10","author":"Patsalos","year":"1999","journal-title":"Rev Contemp Pharmacother."},{"key":"R127-20230814","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1528-1157.1996.tb00651.x","article-title":"Steady state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy","volume":"37","author":"Sachdeo","year":"1996","journal-title":"Epilepsia."},{"key":"R128-20230814","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.0013-9580.2005.55204.x","article-title":"Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine","volume":"46","author":"Britzi","year":"2005","journal-title":"Epilepsia."},{"key":"R129-20230814","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007691-198612000-00005","article-title":"Variable free and total valproic acid concentrations in sole- and multi-drug therapy","volume":"8","author":"Cramer","year":"1986","journal-title":"Ther Drug Monit."},{"key":"R130-20230814","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1978.tb01663.x","article-title":"Disposition of sodium valproate in epileptic patients","volume":"5","author":"Perucca","year":"1978","journal-title":"Br J Clin Pharmacol."},{"key":"R131-20230814","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.seizure.2014.10.010","article-title":"Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy","volume":"25","author":"Dwivedi","year":"2015","journal-title":"Seizure."},{"key":"R132-20230814","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/clpt.1988.194","article-title":"Pharmacokinetics of vigabatrin: implications of creatinine clearance","volume":"44","author":"Haegele","year":"1988","journal-title":"Clin Pharmacol Ther."},{"key":"R133-20230814","first-page":"447","article-title":"The pharmacology and pharmacokinetics of vigabatrin","volume":"6","author":"Patsalos","year":"1995","journal-title":"Rev Contemp Pharmacother."},{"key":"R134-20230814","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1528-1157.1992.tb02202.x","article-title":"Gamma-vinyl-GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in children","volume":"33","author":"Arteaga","year":"1992","journal-title":"Epilepsia."},{"key":"R135-20230814","first-page":"1581","article-title":"Pharmacokinetic studies of AD-810, a new antiepileptic compound","volume":"32","author":"Ito","year":"1982","journal-title":"Arzneimittelforschung."},{"key":"R136-20230814","first-page":"961","article-title":"Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in rats, dogs and monkeys and AD-810 in men","volume":"33","author":"Matsumoto","year":"1983","journal-title":"Arzneimettelforschung."},{"key":"R137-20230814","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/j.1552-4604.1998.tb04406.x","article-title":"Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures","volume":"38","author":"Kochak","year":"1998","journal-title":"J Clin Pharmacol."},{"key":"R138-20230814","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199812000-00001","article-title":"Clinical pharmacology and therapeutic drug monitoring of zonisamide","volume":"20","author":"Mimaki","year":"1998","journal-title":"Ther Drug Monit."},{"key":"R139-20230814","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1528-1157.1987.tb03624.x","article-title":"Zonisamide (CI-912) and cognition: results from preliminary study","volume":"28","author":"Berent","year":"1987","journal-title":"Epilepsia."},{"key":"R140-20230814","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jat\/23.6.452","article-title":"Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration","volume":"23","author":"O'Neal","year":"1999","journal-title":"J Anal Toxicol."},{"key":"R141-20230814","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.forsciint.2005.02.028","article-title":"Oral fiuid collection: the neglected variable in oral fiuid testing","volume":"150","author":"Crouch","year":"2005","journal-title":"Forensic Sci Int."},{"key":"R142-20230814","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00007691-198503000-00006","article-title":"Fallacious results from measuring salivary carbamazepine concentrations","volume":"7","author":"Dickinson","year":"1985","journal-title":"Ther Drug Monit."},{"key":"R143-20230814","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0140-6736(77)92097-9","article-title":"Drug formulation and salivary phenytoin measurements","volume":"1","author":"Ayers","year":"1977","journal-title":"Lancet."},{"key":"R144-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5414\/CPP45047","article-title":"Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers","volume":"45","author":"Lins","year":"2007","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R145-20230814","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R146-20230814","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpba.2016.09.036","article-title":"Dried blood spot analysis of gabapentin as a valid alternative for serum: a bridging study","volume":"132","author":"Sadones","year":"2017","journal-title":"J Pharm Biomed Anal."},{"key":"R147-20230814","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2017.11.005","article-title":"Carbamazepine, lamotrigine, levetiracetam and valproic acid in dried blood spots with liquid chromatography tandem mass spectrometry; method development and validation","volume":"1072","author":"Linder","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R148-20230814","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchromb.2017.01.047","article-title":"Determination of topiramate in dried blood spots using single-quadrupole gas chromatography-mass spectrometry after flash methylation with trimethylanilinium hydroxide","volume":"1046","author":"Hahn","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R149-20230814","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.clinbiochem.2016.12.008","article-title":"Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling","volume":"50","author":"Linder","year":"2017","journal-title":"Clin Biochem."},{"key":"R150-20230814","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00216-010-4048-2","article-title":"Dried plasma spots as an alternative sample collection technique for the quantitative LC-MS\/MS determination of gabapentin","volume":"398","author":"Kolocouri","year":"2010","journal-title":"Anal Bioanal Chem."},{"key":"R151-20230814","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R152-20230814","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FTD.0000000000000502","article-title":"Dried blood spot analysis for therapeutic drug monitoring of antipsychotics: drawbacks of its clinical application","volume":"40","author":"Kloosterboer","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R153-20230814","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00007691-198803000-00021","article-title":"Stability of drug concentrations in plasma stored in serum separator blood collection tubes","volume":"10","author":"Bailey","year":"1988","journal-title":"Ther Drug Monit."},{"key":"R154-20230814","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00007691-200008000-00011","article-title":"Time-dependent absorption of therapeutic drugs by the gel of Greiner Vacuette blood collection tube","volume":"22","author":"Dasgupta","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R155-20230814","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1515\/CCLM.2006.099","article-title":"Evaluation of three different specimen types (serum, plasma lithium heparin and serum gel separator) for analysis of certain analytes: clinical significance of differences in results and efficiency in use","volume":"44","author":"O'Keane","year":"2006","journal-title":"Clin Chem Lab Med."},{"key":"R156-20230814","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00007691-199105000-00009","article-title":"Effect of separator tubes on free and total phenytoin and carbamazepine serum concentrations","volume":"13","author":"Mauro","year":"1991","journal-title":"Ther Drug Monit."},{"key":"R157-20230814","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/ajcp\/101.4.456","article-title":"Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. Volume- and time-dependent reduction in total and free drug concentrations","volume":"101","author":"Dasgupta","year":"1994","journal-title":"Am J Clin Pathol."},{"key":"R158-20230814","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1157.1995.tb01668.x","article-title":"Use of saliva in home monitoring of carbamazepine levels","volume":"36","author":"Rosenthal","year":"1995","journal-title":"Epilepsia."},{"issue":"suppl 7","key":"R159-20230814","first-page":"144","article-title":"Salivary monitoring of lamotrigine and gabapentin","volume":"40","author":"Tennison","year":"1999","journal-title":"Epilepsia."},{"key":"R160-20230814","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200406000-00013","article-title":"Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the US Postal Service","volume":"26","author":"Tennison","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R161-20230814","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.ftd.0000171869.56817.ae","article-title":"Stability of salivary concentrations of the newer antiepileptic drugs in the postal system","volume":"27","author":"Jones","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R164-20230814","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China","volume":"70","author":"Chang","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R165-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1A4 polymorphism and serum concentrations of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res."},{"key":"R166-20230814","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","article-title":"Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7-161C>T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children","volume":"71","author":"Liu","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"R167-20230814","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","article-title":"Influence of the UGT2B7-161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients","volume":"69","author":"Singkham","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R168-20230814","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet Genomics."},{"key":"R169-20230814","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology."},{"key":"R170-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jad.2015.03.018","article-title":"Association between HLA-DRB1*0405, -DQB1*0401 and -DQA1*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan","volume":"179","author":"Ito","year":"2015","journal-title":"J Affect Disord."},{"key":"R171-20230814","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neurol.2017.11.006","article-title":"The HLA-B*15:02 polymorphism and Tegretol\u00ae-induced serious cutaneous reactions in epilepsy: an updated systematic review and meta-analysis","volume":"174","author":"Chouchi","year":"2018","journal-title":"Rev Neurol (Paris)."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:05:11Z","timestamp":1751702711000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":165,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000546","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}